Related Experiment Video
Updated: Sep 8, 2025
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
ADP and Thromboxane Inhibitors Both Reduce Global Contraction of Clot Length, While Thromboxane Inhibition Attenuates
Kevin T Trigani1, Michael E DeCortin1, Scott L Diamond1
1Department of Chemical and Biomolecular Engineering, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Insights
Inhibiting adenosine diphosphate (ADP) and thromboxane A2 (TXA2) signaling pathways reduced platelet clot contraction. Acetylsalicylic acid (ASA) particularly impaired local clot contraction, impacting overall clot structure.
Area of Science:
- Hematology
- Cardiovascular Research
- Pharmacology
Background:
- Platelet contractility is crucial for clot stabilization, but its behavior in flow conditions is less understood.
- Existing studies often examine clot contraction under static conditions, limiting insights into dynamic clot formation.
Purpose of the Study:
- To investigate the impact of inhibiting adenosine diphosphate (ADP) and thromboxane A2 (TXA2) signaling on platelet clot contraction under flow.
- To differentiate the effects of platelet antagonists on global versus local clot contraction dynamics.
Main Methods:
- Utilized a microfluidic device to perfuse whole blood with inhibitors (acetylsalicylic acid, 2-methylthioAMP, MRS-2179) over collagen.
- Observed and quantified platelet clot contraction using automated imaging for both global (length) and local (aggregate surface area) changes after flow cessation.
- Assessed P-selectin expression to identify activated platelets within the clot structure.
Main Results:
- Inhibition of ADP and TXA2 signaling significantly reduced overall platelet fluorescence intensity and global clot contraction.
- Local aggregate contraction was more pronounced than global contraction, but acetylsalicylic acid (ASA) notably diminished local contraction.
- P-selectin expression decreased with combined ADP and TXA2 inhibition, with limited contraction observed in P-selectin-positive platelets.
Conclusions:
- Global clot aggregate contraction is sensitive to inhibition of both ADP and TXA2 signaling pathways.
- ASA demonstrated a more potent inhibitory effect on local clot aggregate contraction compared to global contraction.
- These findings clarify how different antiplatelet agents differentially influence the structural and functional aspects of platelet clots.
Abstract:
Platelet contractility drives clot contraction to enhance clot density and stability. Clot contraction is typically studied under static conditions, with fewer studies of wall-adherent platelet clots formed under flow. We tested the effect of inhibitors of ADP and/or thromboxane A2 (TXA2) signaling on clot contraction. Using an eight-channel microfluidic device, we perfused PPACK-treated whole blood (WB) ± acetylsalicylic acid (ASA), 2-methylthioAMP (2-MeSAMP), and/or MRS-2179 over collagen (100/s) for 7.5 min, then stopped flow to observe contraction for 7.5 minutes. Two automated imaging methods scored fluorescent platelet percent contraction over the no-flow observation period: (1) "global" measurement of clot length and (2) "local" changes in surface area coverage of the numerous platelet aggregates within the clot. Total platelet fluorescence intensity (FI) decreased with concomitant decrease in global aggregate contraction when ASA, 2-MeSAMP, and/or MRS-2179 were present. Total platelet FI and global aggregate contraction were highly correlated ( R 2 = 0.87). In contrast, local aggregate contraction was more pronounced than global aggregate contraction across all inhibition conditions. However, ASA significantly reduced local aggregate contraction relative to conditions without TXA2 inhibition. P-selectin display was significantly reduced by ADP and TXA2 inhibition, but there was limited detection of global or local aggregate contraction in P-selectin-positive platelets across all conditions, as expected for densely packed "core" platelets. Our results demonstrate that global aggregate contraction is inhibited by ASA, 2-MeSAMP, and MRS-2179, while ASA more potently inhibited local aggregate contraction. These results help resolve how different platelet antagonists affect global and local clot structure and function.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:16Clot Retraction and Fibrinolysis
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...